Most HPV infections are not life-threatening. The vast majority clear on their own without causing any health problems. But a small subset of persistent infections with high-risk HPV strains can lead to cancer, and those cancers can be fatal. In 2022, roughly 755,000 people worldwide died from HPV-associated cancers.
Understanding the difference between a common HPV infection and the rare progression to cancer is key to putting your actual risk in perspective.
Most HPV Infections Clear on Their Own
HPV is extremely common. Most sexually active people will contract at least one type at some point. Your immune system typically handles it without you ever knowing you were infected. In a large cohort study tracking men with new HPV infections, 66% cleared the virus within 12 months and 90% cleared it within two years. The numbers are similar for women.
There are over 200 types of HPV. Most cause no symptoms at all. Some cause genital or skin warts, which are annoying but harmless. Only 12 types are classified as high-risk for cancer: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59. Of these, HPV 16 and HPV 18 are responsible for most HPV-related cancers.
How a Persistent Infection Becomes Dangerous
When a high-risk HPV infection doesn’t clear, the virus produces two proteins that interfere with your body’s built-in cancer defenses. One protein disables a key molecule (p53) that normally detects damaged cells and triggers their destruction. The other protein disables a separate brake on cell growth, and unlike the body’s own mechanisms, there’s no upper limit to how much suppression it can cause. The more of this protein present, the further those safety controls drop.
With both of these protective systems offline, infected cells can accumulate genetic damage and divide unchecked. This doesn’t happen overnight. It typically takes 15 to 20 years for a persistent HPV infection to progress to cervical cancer. That long timeline is actually good news: it creates a wide window for screening to catch precancerous changes before they become dangerous.
HPV can cause six types of cancer: cervical, anal, oropharyngeal (throat and tonsil area), penile, vaginal, and vulvar. Cervical cancer accounts for about 46% of all HPV-related deaths globally, and head and neck cancers account for nearly 46% more.
HPV-Related Cancer Risk for Men
There’s a common misconception that HPV is primarily a women’s health issue. That’s increasingly wrong. Oropharyngeal cancer has now surpassed cervical cancer as the most common HPV-related malignancy in the United States, with more than 21,000 cases per year compared to nearly 12,000 cervical cancer cases. It shows up in men four times as often as in women.
While cervical cancer rates dropped 50% between 1975 and 2015 thanks to screening and vaccination, HPV-related throat cancers have increased dramatically over the past three decades. There is currently no routine screening test for oropharyngeal cancer, which makes vaccination even more important for boys and young men.
Early Detection Changes the Outcome
For cervical cancer, the difference between early and late detection is stark. When caught at an early, localized stage, the five-year survival rate is 91%. Once it has spread to nearby tissues or lymph nodes, that drops to 60%. If it has spread to distant parts of the body, the five-year survival rate falls to 19%.
This is why cervical screening (Pap tests and HPV tests) exists. These tests can detect precancerous cell changes years or even decades before cancer develops, allowing treatment that prevents cancer from ever forming. For the other HPV-related cancers, there are no equivalent routine screening programs, which makes prevention through vaccination the primary strategy.
Where You Live Affects Your Risk
Access to screening and vaccination creates enormous disparities. About 94% of the 350,000 cervical cancer deaths in 2022 occurred in low- and middle-income countries. The highest rates of both new cases and deaths are concentrated in sub-Saharan Africa, Central America, and South-East Asia, regions where vaccination programs, screening infrastructure, and treatment services remain limited. In countries with established screening programs, cervical cancer is increasingly preventable and treatable.
Vaccination Dramatically Reduces Cancer Risk
The HPV vaccine is one of the most effective cancer-prevention tools available. In countries with high vaccination coverage (above 50% of the target population), cervical cancer rates have dropped by 34% to 87%. The younger the person is at vaccination, the greater the protection. In one UK study, girls vaccinated at ages 12 to 13 saw an 87% reduction in cervical cancer compared to unvaccinated groups. A Danish study found an 86% reduction among those vaccinated at age 16 or younger.
The vaccine works best before any exposure to high-risk HPV strains, which is why it’s recommended for preteens. But it still provides meaningful benefit for older teens and young adults. The WHO has set targets for every country to reach 90% vaccination of girls by age 15, screen 70% of women by ages 35 and 45, and treat 90% of those found with precancerous changes or invasive cancer, all by 2030. Meeting those benchmarks could put the world on a path to eliminating cervical cancer as a public health problem within this century.
Putting It All Together
HPV itself is not life-threatening for the overwhelming majority of people who contract it. The danger comes from the small fraction of persistent high-risk infections that progress to cancer over many years. That progression is slow, detectable, and increasingly preventable. If you’re vaccinated, your risk of HPV-related cancer drops by the largest margin of any cancer-prevention intervention we have. If you’re past vaccination age, routine cervical screening catches the most common HPV cancer at its most treatable stage. The infection is common; the serious outcomes don’t have to be.